|
1.
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
3.
|
Kajitani T: The general rules for the
gastric cancer study in surgery and pathology. Part I. Clinical
classification. Jpn J Surg. 11:127–139. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Dent DM, Madden MV and Price SK:
Randomized comparison of R1 and R2 gastrectomy for gastric
carcinoma. Br J Surg. 75:110–112. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Robertson CS, Chung SC, Woods SD, Griffin
SM, Raimes SA, Lau JT and Li AK: A prospective randomized trial
comparing R1 subtotal gastrectomy with R3 total gastrectomy for
antral cancer. Ann Surg. 220:176–182. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Cuschieri A, Weeden S, Fielding J, et al:
Patient survival after D1 and D2 resections for gastric cancer:
long-term results of the MRC randomized surgical trial. Surgical
Co-operative Group. Br J Cancer. 79:1522–1530. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Bonenkamp JJ, Hermans J, Sasako M, et al:
Extended lymph-node dissection for gastric cancer. N Engl J Med.
340:908–914. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
The Gastrointestinal Tumor Study Group:
Controlled trial of adjuvant chemotherapy following curative
resection for gastric cancer. Cancer. 49:1116–1122. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Higgins GA, Amadeo JH, Smith DE, Humphrey
EW and Keehn RJ: Efficacy of prolonged intermittent therapy with
combined 5-FU and methyl-CCNU following resection for gastric
carcinoma. A Veterans Administration Surgical Oncology, Group
report. Cancer. 52:1105–1112. 1983. View Article : Google Scholar
|
|
10.
|
Engstrom PF, Lavin PT, Douglass HO Jr and
Brunner KW: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU
therapy for gastric cancer patients. Eastern Cooperative Oncology
Group study (EST 3275). Cancer. 55:1868–1873. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Allum WH, Hallissey MT and Kelly KA:
Adjuvant chemo-therapy in operable gastric cancer. 5 year follow-up
of first British Stomach Cancer Group trial. Lancet. 1:571–574.
1989.PubMed/NCBI
|
|
12.
|
Coombes RC, Schein PS, Chilvers CE, et al:
A randomized trial comparing adjuvant fluorouracil, doxorubicin,
and mitomycin with no treatment in operable gastric cancer.
International Collaborative Cancer Group. J Clin Oncol.
8:1362–1369. 1990.
|
|
13.
|
Krook JE, O’Connell MJ, Wieand HS, et al:
A prospective, randomized evaluation of intensive-course
5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy
for resected gastric cancer. Cancer. 67:2454–2458. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Grau JJ, Estape J, Alcobendas F, Pera C,
Daniels M and Teres J: Positive results of adjuvant mitomycin-C in
resected gastric cancer: a randomised trial on 134 patients. Eur J
Cancer. 29A:340–342. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Lise M, Nitti D, Marchet A, et al: Final
results of a phase III clinical trial of adjuvant chemotherapy with
the modified fluorouracil, doxorubicin and mitomycin regimen in
resectable gastric cancer. J Clin Oncol. 13:2757–2763.
1995.PubMed/NCBI
|
|
16.
|
Macdonald JS, Fleming TR, Peterson RF, et
al: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C
(FAM) versus surgery alone for patients with locally advanced
gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg
Oncol. 2:488–494. 1995. View Article : Google Scholar
|
|
17.
|
Neri B, de Leonardis V, Romano S, et al:
Adjuvant chemotherapy after gastric resection in node-positive
cancer patients: a multicentre randomised study. Br J Cancer.
73:549–552. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cirera L, Balil A, Batiste-Alentorn E, et
al: Randomized clinical trial of adjuvant mitomycin plus tegafur in
patients with resected stage III gastric cancer. J Clin Oncol.
17:3810–3815. 1999.PubMed/NCBI
|
|
19.
|
Bajetta E, Buzzoni R, Mariani L, et al:
Adjuvant chemotherapy in gastric cancer: 5-year results of a
randomised study by the Italian Trials in Medical Oncology (ITMO)
Group. Ann Oncol. 13:299–307. 2002.PubMed/NCBI
|
|
20.
|
De Vita F, Giuliani F, Orditura M, et al:
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil
and etoposide regimen in resected gastric cancer patients: a
randomized phase III trial by the Gruppo Oncologico Italia
Meridionale (GOIM 9602 Study). Ann Oncol. 18:1354–1358. 2007.
|
|
21.
|
Di Costanzo F, Gasperoni S, Manzione L, et
al: Adjuvant chemotherapy in completely resected gastric cancer: a
randomized phase III trial conducted by GOIRC. J Natl Cancer Inst.
100:388–398. 2008.PubMed/NCBI
|
|
22.
|
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM,
Ohyama S, Sasako M and van de Velde CJ: Adjuvant therapy after
curative resection for gastric cancer: meta-analysis of randomized
trials. J Clin Oncol. 11:1441–1447. 1993.PubMed/NCBI
|
|
23.
|
Hermans J and Benekamp K: In replay. J
Clin Oncol. 12:879–880. 1994.
|
|
24.
|
Earle CC and Maroun JA: Adjuvant
chemotherapy after curative resection for gastric cancer in
non-Asian patients: revisiting a meta-analysis of randomised
trials. Eur J Cancer. 35:1059–1064. 1999. View Article : Google Scholar
|
|
25.
|
Mari E, Floriani I, Tinazzi A, et al:
Efficacy of adjuvant chemotherapy after curative resection for
gastric cancer: a meta-analysis of published randomised trials. A
study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi
dell’ Apparato Digerente). Ann Oncol. 11:837–843. 2000.
|
|
26.
|
Gianni L, Panzini I, Tassinari D, Mianulli
AM, Desiderio F and Ravaioli A: Meta-analyses of randomized trials
of adjuvant chemotherapy in gastric cancer. Ann Oncol.
12:1178–1180. 2001.PubMed/NCBI
|
|
27.
|
Panzini I, Gianni L, Fattori PP, et al:
Adjuvant chemotherapy in gastric cancer: a meta-analysis of
randomized trials and a comparison with previous meta-analyses.
Tumori. 88:21–27. 2002.PubMed/NCBI
|
|
28.
|
Hu JK, Chen ZX, Zhou ZG, et al:
Intravenous chemotherapy for resected gastric cancer: meta-analysis
of randomized controlled trials. World J Gastroenterol.
8:1023–1028. 2002.PubMed/NCBI
|
|
29.
|
Janunger KG, Hafstrom L and Glimelius B:
Chemotherapy in gastric cancer: a review and updated meta-analysis.
Eur J Surg. 168:597–608. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Liu TS, Wang Y, Chen SY and Sun YH: An
updated meta-analysis of adjuvant chemotherapy after curative
resection for gastric cancer. Eur J Surg Oncol. 34:1208–1216. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zhao SL and Fang JY: The role of
postoperative adjuvant chemotherapy following curative resection
for gastric cancer: a meta-analysis. Cancer Invest. 26:317–325.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Sun P, Xiang JB and Chen ZY: Meta-analysis
of adjuvant chemotherapy after radical surgery for advanced gastric
cancer. Br J Surg. 96:26–33. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Oba K: Efficacy of adjuvant chemotherapy
using tegafur-based regimen for curatively resected gastric cancer:
update of a meta-analysis. Int J Clin Oncol. 14:85–89. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
35.
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Sakuramoto S, Sasako M, Yamaguchi T, et
al: Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Cunningham D, Starling N, Rao S, et al:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Andre T, Boni C, Navarro M, et al:
Improved overall survival with oxaliplatin, fluorouracil and
leucovorin as adjuvant treatment in stage II or III colon cancer in
the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Kuebler JP, Wieand HS, O’Connell MJ, et
al: Oxaliplatin combined with weekly bolus fluorouracil and
leucovorin as surgical adjuvant chemotherapy for stage II and III
colon cancer: results from NSABP C-07. J Clin Oncol. 25:2198–2204.
2007. View Article : Google Scholar
|
|
40.
|
Kaplan EL and Meier P: Nonparametric
estimation for incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
41.
|
Peto R and Peto J: Asymptotically
efficient rank invariant test procedures. J R Stat Soc.
135A:185–206. 1972.
|
|
42.
|
Cox DR: Regression models and life tables
(with discussion). J R Stat Soc. 4B:187–220. 1972.
|
|
43.
|
Qiu MZ, Teng KY, Ruan DY, et al: Impact of
adjuvant chemotherapy duration on 3-year disease-free survival of
colorectal carcinoma patients after radical resection. Chin J
Cancer. 28:743–748. 2009.PubMed/NCBI
|
|
44.
|
Neugut AI, Matasar M, Wang X, et al:
Duration of adjuvant chemotherapy for colon cancer and survival
among the elderly. J Clin Oncol. 24:2368–2375. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Yen MS, Twu NF, Lai CR, Horng HC, Chao KC
and Juang CM: Importance of delivered cycles and nomogram for
intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol.
114:415–419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Arkenau HT, Bermann A, Rettig K,
Strohmeyer G and Porschen R: 5-Fluorouracil plus leucovorin is an
effective adjuvant chemotherapy in curatively resected stage III
colon cancer: long-term follow-up results of the adjCCA-01 trial.
Ann Oncol. 14:395–399. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Chau I, Norman AR, Cunningham D, et al: A
randomised comparison between 6 months of bolus
fluorouracil/leucovorin and 12 weeks of protracted venous infusion
fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol.
16:549–557. 2005. View Article : Google Scholar
|
|
48.
|
Hershman D, Hall MJ, Wang X, Jacobson JS,
McBride R, Grann VR and Neugut AI: Timing of adjuvant chemotherapy
initiation after surgery for stage III colon cancer. Cancer.
107:2581–2588. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Cold S, During M, Ewertz M, Knoop A and
Moller S: Does timing of adjuvant chemotherapy influence the
prognosis after early breast cancer? Results of the Danish Breast
Cancer Cooperative Group (DBCG). Br J Cancer. 93:627–632. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Jara SC, Ruiz A, Martin M, et al:
Influence of timing of initiation of adjuvant chemotherapy over
survival in breast cancer: a negative outcome study by the Spanish
Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat.
101:215–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Colleoni M, Bonetti M, Coates AS, et al:
Early start of adjuvant chemotherapy may improve treatment outcome
for premenopausal breast cancer patients with tumors not expressing
estrogen receptors. The International Breast Cancer Study Group. J
Clin Oncol. 18:584–590. 2000.
|
|
52.
|
Box B, Lindsey I, Wheeler JM, et al:
Neoadjuvant therapy for rectal cancer: improved tumor response,
local recurrence, and overall survival in nonanemic patients. Dis
Colon Rectum. 48:1153–1160. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Lee SD, Park JW, Park KS, et al: Influence
of anemia on tumor response to preoperative chemoradiotherapy for
locally advanced rectal cancer. Int J Colorectal Dis. 24:1451–1458.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Ferrandina G, Distefano M, Smaniotto D, et
al: Anemia in patients with locally advanced cervical carcinoma
administered preoperative radiochemotherapy: association with
pathological response to treatment and clinical outcome. Gynecol
Oncol. 103:500–505. 2006. View Article : Google Scholar
|
|
55.
|
Shen JG, Cheong JH, Hyung WJ, Kim J, Choi
SH and Noh SH: Pretreatment anemia is associated with poorer
survival in patients with stage I and II gastric cancer. J Surg
Oncol. 91:126–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Park SH, Lee J, Lee SH, et al: Anemia is
the strongest prognostic factor for outcomes of
5-fluorouracil-based first-line chemotherapy in patients with
advanced gastric cancer. Cancer Chemother Pharmacol. 57:91–96.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
De Vita F, Orditura M, Matano E, et al: A
phase II study of biweekly oxaliplatin plus infusional
5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment
of advanced gastric cancer patients. Br J Cancer. 92:1644–1649.
2005.PubMed/NCBI
|
|
58.
|
Fang Y, Wang YJ, Li F and Li J:
Oxaliplatin in combination with calcium folinate and fluorouracil
as neoadjuvant chemotherapy in the treatment of advanced gastric
cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 9:510–512.
2006.PubMed/NCBI
|
|
59.
|
Zhao L, Li XY, Bai CM and Chen SC:
Post-operative adjuvant treatment with oxaliplatin, fluorouracil,
and leucovorin for local advanced gastric cancer. Zhonghua Yi Xue
Za Zhi. 88:1264–1266. 2008.PubMed/NCBI
|
|
60.
|
Matsui M, Kojima O, Kawakami S, Uehara Y
and Takahashi T: The prognosis of patients with gastric cancer
possessing sex hormone receptors. Surg Today. 22:421–425. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Harrison JD, Morris DL, Ellis IO, Jones JA
and Jackson I: The effect of tamoxifen and estrogen receptor status
on survival in gastric carcinoma. Cancer. 64:1007–1010. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Koullias GJ, Kouraklis GP, Raftopoulos IS,
Davaris PS, Papadopoulos SA and Golematis BC: Increased estrogen
receptor and epidermal growth factor receptor gene product
co-expression in surgically resected gastric adenocarcinomas. J
Surg Oncol. 63:166–171. 1996. View Article : Google Scholar : PubMed/NCBI
|
